Citi analyst Joanne Wuensch upgraded Edwards Lifesciences to Buy from Neutral with a price target of $105, up from $98. The stock is positioned to work well into the end of the year, with a reset base business and optimism on the next leg of growth, the analyst tells investors in a research note. The firm sees the company’s TAVR business stabilizing and momentum building in transcatheter mitral and tricuspid therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Roblox downgraded, Western Digital initiated: Wall Street’s top analyst calls
- Edwards Lifesciences upgraded to Buy from Hold at Deutsche Bank
- Edwards Lifesciences launches SAPIEN 3 Ultra RESILIA valve
- Edwards Lifesciences price target raised to $101 from $100 at Barclays
- Edwards Lifesciences price target lowered to $85 from $86 at Canaccord